Cargando…
Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is regarded as a leading cause of cancer-related deaths, and its progression is associated with hypoxia and the induction of hypoxia-inducible factor (HIF). Meloxicam, a selective cyclooxygenase-2 (COX-2) inhibitor, induces cell death in various malignancies. However,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128048/ https://www.ncbi.nlm.nih.gov/pubmed/32273947 http://dx.doi.org/10.1155/2020/7079308 |
_version_ | 1783516476420915200 |
---|---|
author | Zhou, Yinghong Dong, Xiaofeng Xiu, Peng Wang, Xin Yang, Jianrong Li, Lei Li, Zhongchao Sun, Pengfei Shi, Xuetao Zhong, Jingtao |
author_facet | Zhou, Yinghong Dong, Xiaofeng Xiu, Peng Wang, Xin Yang, Jianrong Li, Lei Li, Zhongchao Sun, Pengfei Shi, Xuetao Zhong, Jingtao |
author_sort | Zhou, Yinghong |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is regarded as a leading cause of cancer-related deaths, and its progression is associated with hypoxia and the induction of hypoxia-inducible factor (HIF). Meloxicam, a selective cyclooxygenase-2 (COX-2) inhibitor, induces cell death in various malignancies. However, the underlying mechanism remains to be elucidated in HCC, especially under hypoxic conditions. The alteration of COX-2 and HIF-1α oncogenicity was evaluated in HCC specimens by tissue microarray. Cell viability, angiogenesis assays, and xenografted nude mice were used to evaluate the effects of meloxicam, along with flow cytometry to detect the cell cycle, apoptosis, and mitochondrial membrane potential (ΔΨm) of HCC. qRT-PCR, Western blotting, immunofluorescence, immunohistochemistry, luciferase assay, and RNAi were carried out to determine the HIF-1α signaling affected by meloxicam. In this study, we showed that meloxicam exerts antiproliferative and antiangiogenesis efficacy in vitro and in vivo and causes disruption of mitochondrial membrane potential (ΔΨm), thus leading to caspase-dependent apoptosis under hypoxic environments. Exposure to meloxicam significantly reduced HIF-1α transcriptional activation and expression through sequestering it in the cytoplasm and accelerating degradation via increasing the von Hippel-Lindau tumor suppressor protein (pVHL) in HCC. These data demonstrated that inhibition of HIF-1α by meloxicam could suppress angiogenesis and enhance apoptosis of HCC cells. This discovery highlights that COX-2 specific inhibitors may be a promising therapy in the treatment of HCC. |
format | Online Article Text |
id | pubmed-7128048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-71280482020-04-09 Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma Zhou, Yinghong Dong, Xiaofeng Xiu, Peng Wang, Xin Yang, Jianrong Li, Lei Li, Zhongchao Sun, Pengfei Shi, Xuetao Zhong, Jingtao Oxid Med Cell Longev Research Article Hepatocellular carcinoma (HCC) is regarded as a leading cause of cancer-related deaths, and its progression is associated with hypoxia and the induction of hypoxia-inducible factor (HIF). Meloxicam, a selective cyclooxygenase-2 (COX-2) inhibitor, induces cell death in various malignancies. However, the underlying mechanism remains to be elucidated in HCC, especially under hypoxic conditions. The alteration of COX-2 and HIF-1α oncogenicity was evaluated in HCC specimens by tissue microarray. Cell viability, angiogenesis assays, and xenografted nude mice were used to evaluate the effects of meloxicam, along with flow cytometry to detect the cell cycle, apoptosis, and mitochondrial membrane potential (ΔΨm) of HCC. qRT-PCR, Western blotting, immunofluorescence, immunohistochemistry, luciferase assay, and RNAi were carried out to determine the HIF-1α signaling affected by meloxicam. In this study, we showed that meloxicam exerts antiproliferative and antiangiogenesis efficacy in vitro and in vivo and causes disruption of mitochondrial membrane potential (ΔΨm), thus leading to caspase-dependent apoptosis under hypoxic environments. Exposure to meloxicam significantly reduced HIF-1α transcriptional activation and expression through sequestering it in the cytoplasm and accelerating degradation via increasing the von Hippel-Lindau tumor suppressor protein (pVHL) in HCC. These data demonstrated that inhibition of HIF-1α by meloxicam could suppress angiogenesis and enhance apoptosis of HCC cells. This discovery highlights that COX-2 specific inhibitors may be a promising therapy in the treatment of HCC. Hindawi 2020-03-24 /pmc/articles/PMC7128048/ /pubmed/32273947 http://dx.doi.org/10.1155/2020/7079308 Text en Copyright © 2020 Yinghong Zhou et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhou, Yinghong Dong, Xiaofeng Xiu, Peng Wang, Xin Yang, Jianrong Li, Lei Li, Zhongchao Sun, Pengfei Shi, Xuetao Zhong, Jingtao Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma |
title | Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma |
title_full | Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma |
title_fullStr | Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma |
title_full_unstemmed | Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma |
title_short | Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma |
title_sort | meloxicam, a selective cox-2 inhibitor, mediates hypoxia-inducible factor- (hif-) 1α signaling in hepatocellular carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128048/ https://www.ncbi.nlm.nih.gov/pubmed/32273947 http://dx.doi.org/10.1155/2020/7079308 |
work_keys_str_mv | AT zhouyinghong meloxicamaselectivecox2inhibitormediateshypoxiainduciblefactorhif1asignalinginhepatocellularcarcinoma AT dongxiaofeng meloxicamaselectivecox2inhibitormediateshypoxiainduciblefactorhif1asignalinginhepatocellularcarcinoma AT xiupeng meloxicamaselectivecox2inhibitormediateshypoxiainduciblefactorhif1asignalinginhepatocellularcarcinoma AT wangxin meloxicamaselectivecox2inhibitormediateshypoxiainduciblefactorhif1asignalinginhepatocellularcarcinoma AT yangjianrong meloxicamaselectivecox2inhibitormediateshypoxiainduciblefactorhif1asignalinginhepatocellularcarcinoma AT lilei meloxicamaselectivecox2inhibitormediateshypoxiainduciblefactorhif1asignalinginhepatocellularcarcinoma AT lizhongchao meloxicamaselectivecox2inhibitormediateshypoxiainduciblefactorhif1asignalinginhepatocellularcarcinoma AT sunpengfei meloxicamaselectivecox2inhibitormediateshypoxiainduciblefactorhif1asignalinginhepatocellularcarcinoma AT shixuetao meloxicamaselectivecox2inhibitormediateshypoxiainduciblefactorhif1asignalinginhepatocellularcarcinoma AT zhongjingtao meloxicamaselectivecox2inhibitormediateshypoxiainduciblefactorhif1asignalinginhepatocellularcarcinoma |